Skip to main content

Seattle Genetics Value Stock - Dividend - Research Selection

Seattle Genetics

ISIN: US8125781026, WKN: 602322

Market price date: 01.06.2021
Market price: 154,00 USD




Seattle Genetics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 25-02-2021
Cash flow
Net operating cash flow 856.568.000
Capital Expenditures -82.409.000
Free cash flow 774.158.976
Balance sheet
Total Equity 3.488.100.000
Liabilities & Shareholders equity 4.000.910.000
Income statement
Net income 613.670.000
Eps (diluted) 3,392
Diluted shares outstanding 180.902.000
Net sales/revenue 2.175.540.000

Fundamental ratios calculated on: 01-06-2021

Ratios
Key figures 01-06-2021
Cash flow
P/C 32,52
   
P/FC 35,99
Balance sheet
ROI15,34
ROE87,18
Income statement
P/E45,40
Div. Yield0,00%
P/B7,99
P/S12,81


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSGEN
Market Capitalization27.858.907.136,00 USD
Country
IndicesNASDAQ Comp.,NASDAQ 100
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.seattlegenetics.com


Description of the company

Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.seattlegenetics.com